share_log

HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target

Moomoo 24/7 ·  Apr 4 11:26

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment